Among the retinoic acid receptors (RARα, RARβ and RARγ), the co-administration of ATRA with arsenic trioxide represents a breakthrough front-line treatment for acute promyelocytic leukemia, acting via modulation of RARα activity, offering new avenues for effectively managing the disease (Ma et al., 2016). This evidence concerns the gene RARA and acute promyelocytic leukemia.